Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Three-Stock Lunch: Meta, Disney, and Eli Lilly
03:50pm, Thursday, 28'th Mar 2024
Eva Ados, ERShares chief investment strategist, joins 'Power Lunch' to discuss plays for three stocks, including Meta Platforms, Disney, and Eli Lilly.
This small-cap stock is expected to take off — if its weight-loss pill trial succeeds
03:02pm, Thursday, 28'th Mar 2024
The stock of small-cap Terns Pharmaceuticals Inc. rose 6% on Thursday, amid bullish analyst comment on the company's pipeline, which includes an oral treatment for obesity that one bank believes could
2 Top Biotech Buyout Candidates
02:56pm, Thursday, 28'th Mar 2024
After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i
Hennion & Walsh's Kevin Mahn on his top stock picks: CRWD, MSFT, LLY, RYTM
09:33am, Thursday, 28'th Mar 2024
Kevin Mahn, Hennion & Walsh Asset Management president and CIO, joins 'Squawk Box' to discuss the latest market trends, why he believes AI isn't the only game in town for the markets, and more.
Missed out on Eli Lilly and Novo Nordisk? This pharma stock could be the next ‘big thing'
10:05am, Wednesday, 27'th Mar 2024
Given the pharmaceutical industry's assured success driven by innovation and the development of medications targeting diverse healthcare issues, Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) have
Here's Why Ozempic And Mounjaro Rivals Won't Topple Weight Loss Drugmakers Novo Nordisk And Eli Lilly Anytime Soon
06:26am, Wednesday, 27'th Mar 2024
The world is hooked on weight loss drugs and so is the pharmaceutical industry, but as Big Pharma's biggest players and upstart biotechs rush to join the booming market, experts tell Forbes the domina
Eli Lilly (LLY) Advances While Market Declines: Some Information for Investors
06:51pm, Tuesday, 26'th Mar 2024
In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.
Wall Street Awaits Consumer Confidence Data
11:26am, Tuesday, 26'th Mar 2024
U.S. stock markets saw a pullback on Monday to start a holiday-shortened week. However, Wall Street is likely to record the fifth consecutive winning month despite volatility.
Best Obesity Drug Stock: Eli Lilly, Novo Nordisk, or Viking Therapeutics?
05:51am, Tuesday, 26'th Mar 2024
Eli Lilly has a big winner with Zepbound plus other growth drivers and a promising late-stage pipeline. Novo Nordisk's Ozempic and Wegovy are huge successes with more great drugs potentially on the wa
Wall Street Set to Post Fifth Winning Month Amid Volatility
03:36am, Tuesday, 26'th Mar 2024
Wall Street is likely to record the fifth consecutive winning month despite volatility.
2 More Potential Biotech Buyout Targets
01:07pm, Monday, 25'th Mar 2024
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related produ
Novo Nordisk and Eli Lilly May Finally Have Some Real Competition
06:25am, Monday, 25'th Mar 2024
Demand for obesity and diabetes treatments such as Ozempic, Mounjaro, and Wegovy is off the charts. Novo Nordisk and Eli Lilly manufacture the primary medications used to treat obesity care and diabet
Hedge Funds Are Fleeing Tech: 7 Stocks They're Buying Instead
03:41pm, Sunday, 24'th Mar 2024
It doesn't seem like it based on the mercurial valuations of certain innovators but a rotation away from technology could open doors for stocks hedge funds are buying. Basically, it may be time to con
Here's how much people are willing to spend on weight loss drugs, according to a new survey
07:00am, Saturday, 23'rd Mar 2024
Some patients are willing to pay more for GLP-1 weight loss drugs like Wegovy than others — and it's strongly correlated to their annual income.
Eli Lilly: The Party Is Not Over
05:50am, Saturday, 23'rd Mar 2024
Eli Lilly's stock price has increased by 129% in a year, with a Forward Price-To-Earnings Ratio of 60.4. Lilly's valuation in a base case scenario at $171/share, considering traditional drug revenues.
